1Anplatelet trialists collaborative. Collaborative overview of randomized trials of antiplatet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients[ J]. BMJ, 1994,308:81 - 106.
2Antithrombotic trialists' collaborationve. Collaborate meta - analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high - risk patients [ J ]. BMJ, 2002,324 :71 - 86.
3Mehta J, Mehta P, Burger C, et al. Platelet aggregation studies in coronary artery disease. Effect of aspirin [ J ]. Atherosclerosis, 1978, 31:169 - 175.
4Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusnf S. Aspirin - resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events[ J]. Circulation, 2002,105 : 1650 - 1655.
5Gum PA, Kottke - Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirinresistance among stable patients with cardiovascular disease [ J]. J Am Coll Cardiol, 2003,41:961 -965.
6Bhatt DL. Aspirin resistance: More than just a laboratory curiosity [J]. J Am Coil Cardio, 2004, 43:1127 -1129.
7Peters ILl, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events ( CURE ) study [ J ]. Circulation,2003,108:1682 - 1687.
8CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [ J]. Lancet, 1996,348 : 1329 - 1339.
9Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection [ J]. Gastroenterol Clin North Am, 1996,25:279 - 298.
10Bhatt DL, Scheiman J, Abraham JN, et al. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use[ J]. Circulation, 2008,118 : 1894 - 1909.
